A prospective case-control study to develop biomarkers for individualised visual perturbation responses in epilepsy patients
- Disease/Condition
- Epilepsy
- Study type
- Interventional
- Intervention type
- diagnostic test
- Primary sponsor
- St Vincent's Hospital Melbourne
- Location
- Australia
- Phase
- Not Applicable
- Start date
- Aug 01, 2023
- End date
- Aug 01, 2024
The response to photic stimulation is measured using biomarkers of the EEG signal. These measures will include statistics of the timeseries, signal complexity, spectral information, and spatial synchrony. These will be evaluated together to indicate a composite outcome of cortical excitability.
The primary objective of this study is to characterise the response to perturbation in epilepsy patients and healthy controls. This project will develop objective biomarkers to track changes in cortical excitability. These can be used to develop individualised response profiles that could be used in a clinical context to monitor a patient’s state including seizure risk, to evaluate anti-seizure medication (ASM) efficacy, and to predict outcomes like time to seizure freedom.
- Registry
- Australian New Zealand Clinical Trials Registry
- Trial ID
- ANZCTR12623000728639
- Type
- Non-Device Trial
Access comprehensive clinical trial information for ANZCTR12623000728639 through Pure Global AI's free database. This Not Applicable trial is sponsored by St Vincent's Hospital Melbourne and is currently Not yet recruiting. The study focuses on Epilepsy.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to Australian New Zealand Clinical Trials Registry data, helping medical device and pharmaceutical companies navigate clinical research efficiently.